Abstract
HIV infection represents a serious medical problem, successfully approached ultimately by the introduction of highly active antiretroviral therapy (HAART). One of the classes of drugs present in many HAART regimens is constituted by HIV protease inhibitors (PI), with several of the drugs currently clinically available (saquinavir, ritonavir, indinavir, nelfinavir, amprenavir and lopinavir). In this patent, Pharmacor presents a new class of PIs incorporating amino acyl sulfonamide moieties, which seem to also be effective against HIV isolates resistant to the six clinically used drugs belonging to this class of pharmacological agents.